fda approval in rare leukemias, priority reviews in msi-h cancers and mcc, and more
Published 7 years ago • 148 plays • Length 6:44
Download video MP4
Download video MP3
Similar videos
-
0:31
preview: fda approval in rare leukemias, priority reviews in msi-h cancers and mcc, and more
-
9:04
fda approvals in msi-high cancers, priority reviews in gastric cancer and fl, and more
-
10:46
fda approval in all, priority reviews in cml and breast cancer, and more
-
9:29
fda approvals in all and breast cancer, priority reviews in cml and follicular lymphoma, and more
-
9:10
fda approvals in cml and hodgkin lymphoma, priority review in crc, and more
-
9:02
fda approval in sarcoma, priority reviews in mcrpc and myeloma, and more
-
8:21
fda approval of a biosimilar, priority review in epithelioid sarcoma, and more
-
7:28
fda approvals in pml, nsclc, and breast cancer, priority review in dlbcl, and more
-
7:07
fda approval in crc, priority review in hcc, encouraging data in myeloma trial, and more
-
7:11
review on 2016 fda approvals, halt on aml trials, and more
-
10:00
fda approval in breast cancer, review period extended in aml, 2019 aacr highlights, and more
-
7:27
fda approvals in prostate cancer and endometrial cancer, and priority review in urothelial cancer
-
6:56
fda approves tas-102, nivolumab breakthrough in rcc, two priority reviews, and more
-
1:27
dr. grothey on fda approval of pembrolizumab in msi-high crc
-
9:27
fda approval in bladder cancer, breakthrough therapy designation in dlbcl, and more
-
8:51
fda approvals in nets, breast cancer, aml, a biosimilar, and more
-
10:23
fda approvals in hematologic malignancies, sbla accepted in multiple myeloma, and more
-
7:21
fda approval in breast cancer, breakthrough designations in aml and bladder cancer, and more
-
8:30
fda approvals in bladder cancer, nsclc, aml, hcc, and a breakthrough designation in nsclc
Clip.africa.com - Privacy-policy